Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
Bio-Path Holdings (NASDAQ: BPTH) has announced it will host a live conference call and audio webcast on August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and provide a business overview. The company is developing DNAbilize®, a novel RNAi nanoparticle drug technology administered via intravenous transfusion.
Bio-Path's pipeline includes prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. An IND is expected for BP1003, a STAT3 inhibitor.
Bio-Path Holdings (NASDAQ: BPTH) ha annunciato che ospiterà una conferenza telefonica in diretta e una trasmissione audio via web il 15 agosto 2024 alle 8:30 a.m. ET per riportare i risultati finanziari del secondo trimestre chiuso il 30 giugno 2024 e fornire una panoramica aziendale. L'azienda sta sviluppando DNAbilize®, una nuova tecnologia di farmaco a nanoparticelle RNAi somministrata tramite trasfusione endovenosa.
Il portafoglio di Bio-Path include prexigebersen (BP1001) in fase 2 per i tumori del sangue, BP1001-A in fase 1/1b per i tumori solidi e BP1002 che mira alla proteina Bcl-2 per i tumori del sangue e i tumori solidi. Si prevede un IND per BP1003, un inibitore di STAT3.
Bio-Path Holdings (NASDAQ: BPTH) ha anunciado que realizará una conferencia telefónica en vivo y una transmisión de audio en línea el 15 de agosto de 2024 a las 8:30 a.m. ET para informar sobre los resultados financieros del segundo trimestre finalizado el 30 de junio de 2024 y proporcionar una visión general del negocio. La compañía está desarrollando DNAbilize®, una novedosa tecnología de fármaco nanopartícula de RNAi administrada mediante transfusión intravenosa.
El pipeline de Bio-Path incluye prexigebersen (BP1001) en Fase 2 para cánceres de sangre, BP1001-A en Fase 1/1b para tumores sólidos y BP1002 dirigido a la proteína Bcl-2 para cánceres de sangre y tumores sólidos. Se espera un IND para BP1003, un inhibidor de STAT3.
Bio-Path Holdings (NASDAQ: BPTH)는 2024년 8월 15일 오전 8시 30분 ET에 2024년 6월 30일 종료된 2분기 재무 결과를 보고하고 비즈니스 개요를 제공하기 위한 라이브 컨퍼런스 콜 및 오디오 웹캐스트를 개최할 것이라고 발표했습니다. 이 회사는 정맥 주사를 통해 투여되는 새로운 RNAi 나노입자 약물 기술인 DNAbilize®를 개발하고 있습니다.
Bio-Path의 파이프라인에는 혈액암을 위한 2상 prexigebersen (BP1001), 고형종양을 위한 1/1b상 BP1001-A, 혈액암 및 고형종양을 겨냥하는 Bcl-2 단백질 타겟의 BP1002가 포함되어 있습니다. STAT3 억제제인 BP1003에 대한 IND가 기대됩니다.
Bio-Path Holdings (NASDAQ: BPTH) a annoncé qu'elle organisera une conférence téléphonique en direct et un webinaire audio le 15 août 2024 à 8h30 ET pour rapporter les résultats financiers du deuxième trimestre clos le 30 juin 2024 et fournir un aperçu de l'entreprise. La société développe DNAbilize®, une nouvelle technologie de médicament à nanoparticules ARN interférents administrée par transfusion intraveineuse.
Le pipeline de Bio-Path comprend prexigebersen (BP1001) en phase 2 pour les cancers du sang, BP1001-A en phase 1/1b pour les tumeurs solides et BP1002 ciblant la protéine Bcl-2 pour les cancers du sang et les tumeurs solides. Un IND est attendu pour BP1003, un inhibiteur de STAT3.
Bio-Path Holdings (NASDAQ: BPTH) hat angekündigt, dass am 15. August 2024 um 8:30 Uhr ET ein Live-Conference-Call und ein Audio-Webcast stattfinden werden, um über die Finanzergebnisse für das zweite Quartal zum 30. Juni 2024 zu berichten und einen Überblick über das Geschäft zu geben. Das Unternehmen entwickelt DNAbilize®, eine neuartige RNAi-Nanopartikel-Arzneimitteltechnologie, die durch intravenöse Transfusion verabreicht wird.
Die Pipeline von Bio-Path umfasst prexigebersen (BP1001) in Phase 2 für Blutkrebs, BP1001-A in Phase 1/1b für solide Tumoren und BP1002, das auf das Bcl-2-Protein für Blutkrebs und solide Tumoren abzielt. Für BP1003, einen STAT3-Inhibitor, wird ein IND erwartet.
- DNAbilize® technology yielding a pipeline of RNAi nanoparticle drugs
- Multiple drug candidates in various clinical trial phases
- Diverse portfolio targeting both blood cancers and solid tumors
- None.
HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and to provide a business overview.
To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
When will Bio-Path Holdings (BPTH) report its Q2 2024 financial results?
What is the current status of Bio-Path Holdings' (BPTH) lead product candidate?
How many drug candidates does Bio-Path Holdings (BPTH) have in its pipeline?
What is the delivery method for Bio-Path Holdings' (BPTH) DNAbilize® technology?
